2016 Clinical Trials Treatment 
NORML
APRIL 30, 2020
CDC invites comments specifically on topics focused on using or prescribing opioid pain medications, non-opioid medications, or non-pharmacological treatments.” percent in 2016).” percent in 2016).”
LifeCannMD
AUGUST 2, 2024
Medical Marijuana is increasingly being considered as a potential treatment for severe migraines. More clinical trials are needed to establish definitive efficacy and safety profiles. – Details: The research emphasized the need for controlled clinical trials to better understand the optimal dosages and strains.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
MAY 10, 2022
Anxiety and sleep disorders were some reasons given for prescriptions despite lack of evidence for cannabis treatment, researchers find. Queensland was the source of 51% of prescriptions between 2016 and 2021. We are aware of clinical trials in that space, but not strong evidence.”. The Guardian writes.
Project CBD
OCTOBER 26, 2023
They conducted a double-blind, placebo-controlled phase 2 clinical trial using Sativex® in conjunction with temozolomide to treat recurrent glioblastoma multiforme (GBM). As part of the approval process for all markets, they have conducted critical Phase 2 studies on various conditions, including cancer. mg of THC and 30 mg of CBD.
CannaMD
JUNE 2, 2021
Non-uses were also asked what factors might cause them to consider adding medical marijuana to their treatment regime. More than 80% of survey respondents indicated strong interest in learning more information about a clinical trial, and more than half were interested in enrolling in a clinical trial.
Cannabis Law Report
MAY 10, 2022
Of the 248,000 scripts approved for Australians since inception of national medicinal cannabis scheme in 2016, many related to conditions for which the drug has limited evidence of efficacy, a new University of Sydney study shows. Very few studies have also been done examining cannabis for the treatment of sleep disorders.
Cannabis Law Report
SEPTEMBER 1, 2021
The company recently became the industry’s first firm to list on the NYSE American exchange and their psilocybin clinical trial for depression is making excellent progress. His background is a mix of cognitive psychology, clinical psychology and computer science. After Approval, It’s Off to Treatment Clinics.
Expert insights. Personalized for you.
337 
Let's personalize your content